Unnamed: 0,title,date,stock,sentiment
504507.0,"Guggenheim Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces Price Target of $20",2020-05-27 06:00:00-04:00,FLXN,neutral
504508.0,Flexion Therapeutics Prices ~9.23M Shares At $9.75/Share,2020-05-21 07:31:00-04:00,FLXN,positive
504509.0,Flexion Therapeutics Announces A $75M Common Stock Offering,2020-05-20 16:02:00-04:00,FLXN,neutral
504510.0,"Flexion Therapeutics Inc Says Continues To Expect To Experience A Material Decline In Revenues For Remainder Of 2020, And Possibly Longer",2020-05-19 07:37:00-04:00,FLXN,neutral
504511.0,"Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $20",2020-05-08 10:49:00-04:00,FLXN,negative
504512.0,"RBC Capital Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $18",2020-05-08 09:13:00-04:00,FLXN,negative
504513.0,"Flexion Therapeutics Q1 EPS $(0.950) Beats $(0.990) Estimate, Sales $20.127M Beat $19.800M Estimate",2020-05-07 17:51:00-04:00,FLXN,neutral
504514.0,Flexion Therapeutics Highlights Publication Of New Abstract Accepted At Osteoarthritis Research Society International OARSI 2020,2020-05-01 09:03:00-04:00,FLXN,positive
504515.0,"Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $30",2020-04-30 08:36:00-04:00,FLXN,negative
504516.0,"Raymond James Maintains Strong Buy on Flexion Therapeutics, Lowers Price Target to $20",2020-04-27 11:52:00-04:00,FLXN,positive
504517.0,"Flexion Therapeutics Announces Positive Preclinical Data Supporting Development Of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate For Post-Pain",2020-04-27 07:32:00-04:00,FLXN,positive
504518.0,"Benchmark Maintains Buy on Flexion Therapeutics, Lowers Price Target to $17",2020-04-02 08:34:00-04:00,FLXN,negative
504519.0,"Flexion Therapeutics Announces ZILRETTA License Agreement; Co. To Receive Upfront Payment Of $10M, Up To $32.5M In Milestones",2020-04-01 07:01:00-04:00,FLXN,positive
504520.0,"Flexion Therapeutics Sees Prelim. Q4 Sales $23.7M vs $24.15M Est., Prelim. FY19 Sales $73M vs $73.43M Est.; Sees FY20 Product Revenues $120M-$135M",2020-01-09 16:03:00-05:00,FLXN,neutral
504521.0,"Needham Maintains Buy, $36 Target On Flexion Therapeutics Notes 'Overall, we believe FLXN achieved its key goal of removing the LOU, which was a source of confusion for many physicians, and is now in a position to better promote Zilretta usage'",2019-12-27 10:06:00-05:00,FLXN,positive
504522.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB",2019-12-27 08:46:00-05:00,FLXN,negative
504523.0,"Raymond James Maintains Strong Buy on Flexion Therapeutics, Raises Price Target to $28",2019-12-27 07:27:00-05:00,FLXN,positive
504524.0,Flexion Therapeutics shares are trading higher after the company announced FDA approval of sNDA to revise ZILRETTA product label.,2019-12-26 16:17:00-05:00,FLXN,positive
504525.0,Flexion Reports FDA Approval Of Supplemental New Drug Application To Revise ZILRETTA Product Label,2019-12-26 16:16:00-05:00,FLXN,positive
504526.0,Flexion Therapeutics Enrolls First Patients In Phase 2 Trial Of ZILRETTA In OA Of The Shoulder And Adhesive Capsulitis,2019-12-17 07:34:00-05:00,FLXN,neutral
504527.0,"Craig-Hallum Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces $24 Price Target",2019-12-05 07:44:00-05:00,FLXN,neutral
504528.0,"BTIG Research Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces $27 Price Target",2019-11-25 07:00:00-05:00,FLXN,neutral
504529.0,Flexion Therapeutics Presents ZILRETTA Efficacy Data at the AAHKS and ACR Annual Meetings,2019-11-11 07:36:00-05:00,FLXN,neutral
504530.0,"Flexion Therapeutics Q3 EPS $(1) Misses $(0.96) Estimate, Sales $21.786M Beat $19.01M Estimate",2019-11-07 16:02:00-05:00,FLXN,negative
504531.0,Flexion Therapeutics Announces FDA Clearance Of Investigational New Drug Application For FX201 Gene Therapy Candidate For The Treatment Of Osteoarthritis,2019-10-31 07:32:00-04:00,FLXN,neutral
504532.0,Flexion Therapeutics Notified by the FDA That it Needs More Time to Review the Supplemental New Drug Application for ZILRETTA,2019-10-14 07:04:00-04:00,FLXN,neutral
504533.0,Flexion Therapeutics Names CEO Mike Clayman Chair,2019-09-27 08:08:00-04:00,FLXN,neutral
504534.0,Flexion Therapeutics And Xenon Pharmaceuticals Announce Flexion's Acquisition Of An Investigational NaV1.7 Inhibitor For The Treatment Of Post-Operative Pain; Xenon Received $3M Upfront And Is Eligible For Additional Milestones,2019-09-09 16:03:00-04:00,FLXN,negative
504535.0,Flexion Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-06 16:34:00-04:00,FLXN,positive
504536.0,"Flexion Therapeutics Q2 EPS $(0.96) Beats $(1.05) Estimate, Sales $16.953M Beat $14.7M Estimate",2019-08-06 16:21:00-04:00,FLXN,neutral
504537.0,Flexion Therapeutics Highlights Presentation Of New Data Evaluating Repeat Administration Of ZILRETTA In Patients With Advanced Knee OA,2019-07-15 07:35:00-04:00,FLXN,positive
504538.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,FLXN,negative
504539.0,Flexion Therapeutics Announces Issuance Of New US Patent Covering FX201 A Gene Therapy Product Candidate For The Treatment Of Osteoarthritis,2019-06-05 08:44:00-04:00,FLXN,neutral
504540.0,"Flexion Therapeutics shares are trading higher after the company announced a pooled analysis of data from three Phase 2/3 clinical trials of medications with ZILRETTA were published in ""Pain and Therapy.""",2019-05-10 10:36:00-04:00,FLXN,negative
504541.0,Flexion Therapeutics Highlights Publication Of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA In 'Pain And Therapy',2019-05-10 07:33:00-04:00,FLXN,neutral
504542.0,"Benchmark Upgrades Flexion Therapeutics, Inc. - Common Stock to Buy",2019-05-09 09:25:00-04:00,FLXN,neutral
504543.0,"Flexion Therapeutics Q1 EPS $(1.09) Misses $(1.08) Estimate, Sales $10.564M Miss $11.16M Estimate",2019-05-08 16:41:00-04:00,FLXN,negative
504544.0,Flexion Therapeutics Highlights Publication Of Analysis Of Patients With Unilateral Knee OA From Pivotal Trial Of ZILRETTA,2019-04-24 16:39:00-04:00,FLXN,neutral
504545.0,Flexion Therapeutics Highlights Publication Of Independent Data Review Of ZILRETTA In The Journal Drugs,2019-04-02 07:34:00-04:00,FLXN,neutral
504546.0,Flexion Therapeutics Q4 Sales $9.5M Beat $9.38M Estimate,2019-02-28 17:01:00-05:00,FLXN,neutral
504547.0,Flexion Reports New In Vitro Data Showing Protective Effects Of Triamcinolone Acetonide On Cartilage,2019-02-21 17:31:00-05:00,FLXN,neutral
504548.0,Flexion Therapeutics Highlights Publication Of Data from Repeat Administration Trial of ZILRETTAÂ® in Rheumatology and Therapy In 'Rheumatology And Therapy',2019-02-11 16:14:00-05:00,FLXN,neutral
504549.0,Benchmark Downgrades Flexion Therapeutics to Hold,2019-01-04 07:41:00-05:00,FLXN,neutral
504550.0,Flexion Therapeutics shares are trading lower after the company missed Q4 EPS and revenue estimates.,2019-01-03 16:18:00-05:00,FLXN,negative
504551.0,Flexion Sees FY19 Product Sales $65M-$80M,2019-01-03 16:02:00-05:00,FLXN,neutral
504552.0,Flexion Sees Q4 Sales ~$9.5M vs $10.25M Estimate; FY18 Sales ~$22.5M vs $23.16M Est.,2019-01-03 16:02:00-05:00,FLXN,neutral
504553.0,"Flexion Reports Enrollment Of First Patient In Phase 3 Trial OF ZILRETTA In Hip Osteoarthritis, Offers Results From SHIP Study",2019-01-02 16:51:00-05:00,FLXN,neutral
504554.0,Flexion Therapeutics Submits Supplemental New Drug Application For ZILRETTA,2018-12-17 16:30:00-05:00,FLXN,neutral
504555.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,FLXN,negative
504556.0,"Flexion Therapeutics Q3 EPS $(1.15) Beats $(1.21) Estimate, Sales $6.99M Beat $6.75M Estimate",2018-11-07 16:52:00-05:00,FLXN,neutral
504557.0,Flexion Therapeutics Announces the Product Specific Medicare & Medicaid Code for ZILRETTA Will Switch From Q to J,2018-11-05 06:45:00-05:00,FLXN,neutral
504558.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,FLXN,negative
504559.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,FLXN,negative
504560.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,FLXN,negative
504561.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,FLXN,negative
504562.0,"Stocks Which Set New 52-Week Low Yesterday, September 26th",2018-09-27 09:14:00-04:00,FLXN,negative
504563.0,"Stocks Which Set New 52-Week Low Yesterday, September 25th",2018-09-26 12:44:00-04:00,FLXN,negative
504564.0,"Stocks Which Set New 52-Week Low Yesterday, September 24th",2018-09-25 09:16:00-04:00,FLXN,negative
504565.0,"Stocks Which Set New 52-Week Low Friday, September 21st",2018-09-24 09:48:00-04:00,FLXN,negative
504566.0,"Stocks Which Set New 52-Week Low Yesterday, September 20th",2018-09-21 08:19:00-04:00,FLXN,negative
504567.0,Flexion Says Phase 2 Data Evaluating Zilretta Showed Lower Blood Glucose Levels Following Zilretta Injection Compared To TAcs Injeciton,2018-09-10 09:06:00-04:00,FLXN,negative
504568.0,"Flexion Therapeutics Q2 EPS $(1.16) Beats $(1.23) Estimate, Sales $3.8M Miss $4.26M Estimate",2018-08-07 16:41:00-04:00,FLXN,negative
504569.0,"Benchmark Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces $39 Price Target",2018-06-28 07:18:00-04:00,FLXN,neutral
504570.0,"Flexion Therapeutics Q1 EPS $(1.10) Beats $(1.33) Estimate, Sales $2.19M Miss $2.46M Estimate",2018-05-08 16:18:00-04:00,FLXN,negative
504571.0,Flexion Therapeutics Names David Arkowitz CFO,2018-05-07 07:32:00-04:00,FLXN,neutral
504572.0,Flexion Therapeutics Reports CMS Recommends ZILRETTA For Unique J Code,2018-05-04 07:40:00-04:00,FLXN,positive
504573.0,"Flexion Therapeutics Says Avg. Time To Administer The 2nd Administration Of ZILRETTA Was 16.6 Weeks, 74% Of Patients Received This Between Weeks 16 And 24; Co. Reports Magnitude And Duration Of Pain Relief From THe Injection Is In Line With Phase 3 Trial",2018-04-26 07:35:00-04:00,FLXN,negative
504574.0,Flexion Therapeutics Announces Pivotal Phase 3 ZILRETTA Study Results Published In Jounral of Bone and Joint Surgery,2018-04-18 16:21:00-04:00,FLXN,neutral
504575.0,"Flexion Therapeutics Reports FY17 EPS $(4.16) vs $(3.81) Est., Sales $355K vs $580K Est.",2018-03-08 16:25:00-05:00,FLXN,neutral
504576.0,"Berenberg Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces $42.00 Price Target",2018-02-01 08:11:00-05:00,FLXN,neutral
504577.0,Earler 13G/A Filing Shows BlackRock Reporting 7.1% Stake In Flexion Therapeutics,2018-01-25 13:58:00-05:00,FLXN,neutral
504578.0,Flexion Therapeutics Enrolls First Patient In ZILRETTA SHIP Phase 2 Study,2017-12-18 16:08:00-05:00,FLXN,neutral
504579.0,"Flexion Therapeutics Reports Purchase GeneQuine Biotherapeutics' Global Rights To GQ-203 For Upfront Payment Of $2M, Plus Milestone Payments Up To $8.7M",2017-12-13 16:08:00-05:00,FLXN,neutral
504580.0,Flexion Therapeutics Names Scott Kelley CMO,2017-12-11 16:06:00-05:00,FLXN,neutral
504581.0,"Flexion Therapeutics Reports Enrollment Of First Patient In Phase 2 Pharmacokinetics, Safety Study Of ZILRETTA In Bilateral Osteoarthritis Of The Knee",2017-12-07 16:57:00-05:00,FLXN,positive
504582.0,Flexion Therapeutics Enrolls First Patient In Phase 2 ZILRETTA Study,2017-12-07 16:35:00-05:00,FLXN,neutral
504583.0,Flexion Therapeutics Reports Q3 EPS $(1.07) vs $(0.98) Est.,2017-11-06 16:08:00-05:00,FLXN,neutral
504584.0,Flexion Therapeutics Prices Offering Of 4.8M Shares At $25.50/Share,2017-10-11 17:55:00-04:00,FLXN,positive
504585.0,Flexion Therapeutics Announces 4M Share Common Stock Offering,2017-10-10 16:05:00-04:00,FLXN,positive
504586.0,Flexion Shares Resume Trading up 16%,2017-10-06 15:20:00-04:00,FLXN,positive
504587.0,Flexion Therapeutics to Resume Trading at 3:20pm EDT,2017-10-06 15:05:00-04:00,FLXN,neutral
504588.0,Flexion's Zilretta Label Includes Results from Data from a Diabetes Study,2017-10-06 15:01:00-04:00,FLXN,neutral
504589.0,Flexion Therapeutics Announces FDA Approval of Zilretta for Osteoarthritis Knee Pain,2017-10-06 15:00:00-04:00,FLXN,negative
504590.0,"Flexion Halted, News Pending",2017-10-06 14:53:00-04:00,FLXN,neutral
504591.0,REMINDER: Flexion Has PDUFA Date For Zilretta Today,2017-10-06 09:27:00-04:00,FLXN,neutral
504592.0,"Watching Flexion, AxelRx, Agile Therapeutics Shares Premarket Thurs. Following Reuters Highlighting 'RBC sees 3 small-cap drugmakers as candidates for takeover'; Stocks Not Moving",2017-10-05 07:20:00-04:00,FLXN,positive
504593.0,NantKwest Appoints Flexion Therapeutics CFO To Its Board,2017-09-22 16:48:00-04:00,FLXN,neutral
504594.0,"Northland Securities Initiates Coverage On Flexion Therapeutics with Outperform Rating, Announces $40.00 Price Target",2017-08-24 09:10:00-04:00,FLXN,positive
504595.0,Flexion Therapeutics Reports Q2 Loss/Share $(0.91) vs. $(0.82) Est.,2017-08-08 16:45:00-04:00,FLXN,neutral
504596.0,Flexion Shares Spiking Higher As CEO Currently Speaking On CNBC About America's Opioid Crisis,2017-05-23 13:49:00-04:00,FLXN,negative
504597.0,Flexion Therapeutics Reports Q1 EPS $(0.75) vs $(0.72) Est.,2017-05-04 16:53:00-04:00,FLXN,neutral
504598.0,Flexion Therapeutics Names Yamo Deniz Chief Medical Officer,2017-04-07 07:30:00-04:00,FLXN,neutral
504599.0,Flexion Therapeutics Reports Issuance of 2 New Patents Further Strengthening Intellectual Property Protection (IP) for Zilretta,2017-04-04 07:30:00-04:00,FLXN,positive
504600.0,FiercePharma Says Sanofi On Verge Of $1B-Plus Deal For Flexion According To Sources,2017-03-23 10:26:00-04:00,FLXN,neutral
504601.0,"Flexion Announces PDUFA Date Of Oct. 6, 2017 For Zilretta",2017-03-09 16:20:00-05:00,FLXN,neutral
504602.0,Flexion Reports FY16 EPS $(2.84) vs $(2.75) Est.,2017-03-09 16:19:00-05:00,FLXN,neutral
504603.0,Flexion Therapeutics Begins Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta,2017-02-23 07:35:00-05:00,FLXN,positive
504604.0,Flexion Therapeutics Announces New Drug Application for Zilretta Accepted By FDA,2017-02-07 07:31:00-05:00,FLXN,positive
504605.0,Raymond James Initiates Coverage On Flexion Therapeutics at Strong Buy,2016-12-22 08:10:00-05:00,FLXN,positive
504606.0,"Lake Street Assumes Flexion Therapeutics at Buy, Announces $38.00 PT",2016-09-06 08:27:00-04:00,FLXN,neutral
504607.0,BMO Capital Initiates Coverage on Flexion Therapeutics at Outperform,2016-06-29 06:26:00-04:00,FLXN,neutral
504608.0,"Earlier Janney Capital Assumed Flexion Therapeutics at Buy, Announces $27.00 PT",2015-12-10 11:54:00-05:00,FLXN,neutral
504609.0,"MLV & Co Initiates Coverage on Flexion Therapeutics at Buy, Announces $38.00 PT",2015-03-30 16:31:00-04:00,FLXN,neutral
504610.0,"RBC Capital Initiates Coverage on Flexion Therapeutics at Outperform, Announces $37.00 PT",2015-02-16 09:06:00-05:00,FLXN,neutral
504611.0,Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee,2015-02-02 16:07:00-05:00,FLXN,neutral
504612.0,"Summer Street Initiates Coverage on Flexion Therapeutics at Buy, Announces $25.00 PT",2014-08-14 09:22:00-04:00,FLXN,neutral
504613.0,Flexion Therapeutics Reports Q2 EPS of $(0.38) vs $(0.52) Est,2014-08-07 16:58:00-04:00,FLXN,neutral
504614.0,Flexion Therapeutics Reports Q1 EPS of $(0.86) vs $(0.52) Est,2014-05-08 16:17:00-04:00,FLXN,neutral
504615.0,Flexion Therapeutics Reports FY13 EPS of $(23.02),2014-03-27 08:02:00-04:00,FLXN,neutral
504616.0,"Janney Capital Initiates Coverage on Flexion Therapeutics at Buy, Announces $25.00 PT",2014-03-19 16:40:00-04:00,FLXN,neutral
504617.0,"Needham Initiates Coverage on Flexion Therapeutics at Buy, Announces $26.00 PT",2014-03-10 07:40:00-04:00,FLXN,neutral
504618.0,"BMO Capital Initiates Coverage on Flexion Therapeutics at Outperform, Announces $33.00 PT",2014-03-10 07:38:00-04:00,FLXN,neutral
504619.0,Wells Fargo Initiates Coverage on Flexion Therapeutics at Outperform,2014-03-10 07:32:00-04:00,FLXN,positive
504620.0,Flexion Therapeutics Prices 5M Share IPO at $13.00/Share,2014-02-11 19:18:00-05:00,FLXN,positive
504621.0,"Flexion Therapeutics Files $86.25M IPO, Planning to List on NASDAQ Under 'FLXN'",2014-01-08 16:14:00-05:00,FLXN,neutral
